Zheng et al. designed biomimetic co-assembled nanodrug of doxorubicin and berberine, and found that it inhibits tumor growth and pulmonary metastasis by blocking HMGB1/TLR4 signaling, which provides novel evidence to develop safe and efficient nanodrugs for breast cancer 134. This evidence concerns the gene TLR4 and breast carcinoma.